+

WO1992007832A3 - Piperazines substituees utilisees comme agents de traitement du systeme nerveux central - Google Patents

Piperazines substituees utilisees comme agents de traitement du systeme nerveux central Download PDF

Info

Publication number
WO1992007832A3
WO1992007832A3 PCT/US1991/008058 US9108058W WO9207832A3 WO 1992007832 A3 WO1992007832 A3 WO 1992007832A3 US 9108058 W US9108058 W US 9108058W WO 9207832 A3 WO9207832 A3 WO 9207832A3
Authority
WO
WIPO (PCT)
Prior art keywords
nervous system
central nervous
substituted piperazines
system agents
agents
Prior art date
Application number
PCT/US1991/008058
Other languages
English (en)
Other versions
WO1992007832A2 (fr
Inventor
Shelly Glase
Juan Carlos Jaen
Sarah Jane Smith
Lawrence David Wise
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Priority to EP92901210A priority Critical patent/EP0556329B1/fr
Priority to JP4502239A priority patent/JP3064418B2/ja
Priority to CA002094703A priority patent/CA2094703C/fr
Priority to DE69116378T priority patent/DE69116378T2/de
Publication of WO1992007832A2 publication Critical patent/WO1992007832A2/fr
Publication of WO1992007832A3 publication Critical patent/WO1992007832A3/fr
Priority to GR960400878T priority patent/GR3019490T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des pipérazines substituées ainsi que leurs dérivés et des procédés de préparation ainsi qu'une composition pharmaceutique desdites pipérazines, lesquelles sont utilisées comme agents de traitement du système nerveux central et sont particulièrement utiles comme agents dopaminergiques, neuroleptiques et antihypertensifs, elles sont également utilisées dans le traitement d'état associés à l'hyperprolactinémie et de troubles du système nerveux central.
PCT/US1991/008058 1990-11-05 1991-10-29 Piperazines substituees utilisees comme agents de traitement du systeme nerveux central WO1992007832A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP92901210A EP0556329B1 (fr) 1990-11-05 1991-10-29 Piperazines substituees utilisees comme agents de traitement du systeme nerveux central
JP4502239A JP3064418B2 (ja) 1990-11-05 1991-10-29 中枢神経系剤としての置換ピペラジン
CA002094703A CA2094703C (fr) 1990-11-05 1991-10-29 Derives de la piperazine, agents therapeutiques pour le systeme nerveux central
DE69116378T DE69116378T2 (de) 1990-11-05 1991-10-29 Substituierte piperazine als mittel zur behandlung des zentrallen nervensystems
GR960400878T GR3019490T3 (en) 1990-11-05 1996-04-02 Substituted piperazines as central nervous system agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60930090A 1990-11-05 1990-11-05
US609,300 1990-11-05
US07/778,247 US5270312A (en) 1990-11-05 1991-10-24 Substituted piperazines as central nervous system agents
US778,247 1991-10-24

Publications (2)

Publication Number Publication Date
WO1992007832A2 WO1992007832A2 (fr) 1992-05-14
WO1992007832A3 true WO1992007832A3 (fr) 1992-06-11

Family

ID=27086004

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/008058 WO1992007832A2 (fr) 1990-11-05 1991-10-29 Piperazines substituees utilisees comme agents de traitement du systeme nerveux central

Country Status (11)

Country Link
US (1) US5270312A (fr)
EP (1) EP0556329B1 (fr)
JP (1) JP3064418B2 (fr)
AT (1) ATE132855T1 (fr)
AU (1) AU645873B2 (fr)
CA (1) CA2094703C (fr)
DE (1) DE69116378T2 (fr)
DK (1) DK0556329T3 (fr)
ES (1) ES2084996T3 (fr)
GR (1) GR3019490T3 (fr)
WO (1) WO1992007832A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
ZA9610741B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
WO2001016121A1 (fr) * 1999-08-31 2001-03-08 Merck & Co., Inc. Composes heterocycliques et procedes d'utilisation de ceux-ci
US7045543B2 (en) 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
EP1817305A2 (fr) * 2004-11-16 2007-08-15 Neurochem (International) Limited Composes pour le traitement de maladies associees au snc et a la proteine amyloide
AU2005326962A1 (en) 2004-12-22 2006-08-17 Bellus Health (International) Limited Methods and compositions for treating amyloid-related diseases
US20070232556A1 (en) * 2006-03-31 2007-10-04 Montine Thomas J Methods and compositions for the treatment of neurological diseases and disorders
US20100316626A1 (en) * 2006-08-11 2010-12-16 The Government Of The United States Of America As Represented By The Secretary Methods for treatment and diagnosis of psychiatric disorders
PL2089417T3 (pl) 2006-10-12 2015-07-31 Bhi Lp Sposoby, związki, kompozycje i nośniki dostarczające kwas 3-amino-1-propanosulfonowy
WO2010035261A2 (fr) 2008-09-29 2010-04-01 Ben Gurion University Of The Negev Research And Development Authority Beta-peptides amyloides et procédés d'utilisation associés
CA3006745C (fr) * 2010-11-05 2021-03-30 Oat Agrio Co., Ltd. Ethynylphenylamidine ou l'un de ses sels, son procede de production et fongicide pour applications agricoles et horticoles
CN104163813B (zh) * 2013-05-16 2017-02-01 广东东阳光药业有限公司 取代的吲哚化合物及其使用方法和用途
CN104337812B (zh) 2013-07-29 2018-09-14 广东东阳光药业有限公司 取代的杂芳基化合物及其使用方法和用途
WO2016192657A1 (fr) 2015-06-03 2016-12-08 Sunshine Lake Pharma Co., Ltd. Composés de pipérazine substitués, leurs procédés d'utilisation et leurs utilisations
WO2018226992A1 (fr) 2017-06-07 2018-12-13 Adrx, Inc. Inhibiteur d'agrégation de tau
US11453701B2 (en) 2017-08-18 2022-09-27 Adrx, Inc. Tau aggregation peptide inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1055548A (en) * 1965-08-23 1967-01-18 Acraf New substituted 1-aryl-3-aminopropynes and process for their preparation
EP0211457A2 (fr) * 1985-07-31 1987-02-25 Janssen Pharmaceutica N.V. (4-Pipérazinyl substituée)pyridazines
EP0345533A1 (fr) * 1988-05-27 1989-12-13 Warner-Lambert Company 2 Amino thiazoles substitués comme agents dopaminergiques
EP0345808A1 (fr) * 1988-06-10 1989-12-13 Bristol-Myers Squibb Company 1-Indolylalkyl-4-(pyridinyl substitué)-pipérazines
EP0361271A1 (fr) * 1988-09-28 1990-04-04 Kabi Pharmacia AB Dérivés de pyridyle et de pyrimidyle

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545561A1 (de) * 1965-08-23 1969-12-11 Acraf Verfahren zur Herstellung von pharmakologisch aktiven N,N-disubstituierten 1-Aryl-3-aminopropinen
US3856790A (en) * 1970-01-06 1974-12-24 American Home Prod Cyclic amides of 1,4-diaminobut-2-yne
US4891375A (en) * 1988-01-13 1990-01-02 Pfizer Inc. Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1055548A (en) * 1965-08-23 1967-01-18 Acraf New substituted 1-aryl-3-aminopropynes and process for their preparation
EP0211457A2 (fr) * 1985-07-31 1987-02-25 Janssen Pharmaceutica N.V. (4-Pipérazinyl substituée)pyridazines
EP0345533A1 (fr) * 1988-05-27 1989-12-13 Warner-Lambert Company 2 Amino thiazoles substitués comme agents dopaminergiques
EP0345808A1 (fr) * 1988-06-10 1989-12-13 Bristol-Myers Squibb Company 1-Indolylalkyl-4-(pyridinyl substitué)-pipérazines
EP0361271A1 (fr) * 1988-09-28 1990-04-04 Kabi Pharmacia AB Dérivés de pyridyle et de pyrimidyle

Also Published As

Publication number Publication date
DK0556329T3 (da) 1996-05-06
CA2094703A1 (fr) 1992-05-06
AU645873B2 (en) 1994-01-27
CA2094703C (fr) 2002-03-26
ATE132855T1 (de) 1996-01-15
AU9061991A (en) 1992-05-26
DE69116378T2 (de) 1996-06-13
DE69116378D1 (de) 1996-02-22
JPH06501487A (ja) 1994-02-17
EP0556329B1 (fr) 1996-01-10
JP3064418B2 (ja) 2000-07-12
WO1992007832A2 (fr) 1992-05-14
ES2084996T3 (es) 1996-05-16
US5270312A (en) 1993-12-14
GR3019490T3 (en) 1996-07-31
EP0556329A1 (fr) 1993-08-25

Similar Documents

Publication Publication Date Title
AU6770290A (en) Substituted cyclohexanols as central nervous system agents
WO1992007832A3 (fr) Piperazines substituees utilisees comme agents de traitement du systeme nerveux central
US5151423B1 (en) Heterocyclic n-oxide derivatives of substituted benzo(5,6)cycloheptapyridines, compositions and methods of use
GR3019782T3 (en) Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents
BG100830A (en) Naphthylamides as central nervous system agents
MY102986A (en) Benzo (5,6) cycloheptapyridines, compositions and methods of use
SG46641A1 (en) 1,3-Substituted cycloalkenes and cycloalkanes as central nervous system agents
MY107354A (en) Substituted cyclohexenes as central nervous system agents
EP0260642A3 (fr) Dérivés d'hexahydroquinoline condensés en [f] avec thiazolo comme agents dopaminergiques
CA2180155A1 (fr) Naphtylamides comme agents actifs sur le systeme nerveux central
MX9101928A (es) Piperazinas substituidas como agentes del sistema nervioso central.
MX9302225A (es) Cicloalquenos y cicloalcanos 1,3-substituidos como agentes del sistema nervioso central.
MX9206635A (es) Cicloalquenos y cicloalcanos 1,3-substituidos como agentes del sistema nervioso central.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2094703

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1992901210

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992901210

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1992901210

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载